
Join to View Full Profile
19260 SW 65th AveSuite 435Tualatin, OR 97062
Phone+1 503-692-2032
Fax+1 503-692-4450
Are you Dr. Schnadig?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Ian Schnadig, MD is an oncologist in Tualatin, Oregon. He is currently licensed to practice medicine in Oregon, Washington, and New Mexico. He is a Physician at Chairman Pharmacy & Therapeutics.
Education & Training
- Oregon Health & Science University (OHSU Health)Fellowship, Hematology and Medical Oncology, 2005 - 2008
- Oregon Health & Science University (OHSU Health)Residency, Internal Medicine, 2002 - 2005
- Rush Medical College of Rush University Medical CenterClass of 2002
Certifications & Licensure
- WA State Medical License 2010 - 2026
- OR State Medical License 2010 - 2025
- NM State Medical License 2008 - 2010
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- 22 citationsPhase Ib/II Study of Enzalutamide with Samotolisib (LY3023414) or Placebo in Patients with Metastatic Castration-Resistant Prostate Cancer.Christopher J Sweeney, Ivor J Percent, Sunil Babu, Jennifer L Cultrera, Bryan A Mehlhaff
Clinical Cancer Research. 2022-06-01 - 53 citationsSafety and Efficacy of Nivolumab in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma: Results From the Phase IIIb/IV CheckMate 374 Study.Nicholas J Vogelzang, Mark R Olsen, Joshua J McFarlane, Edward Arrowsmith, Todd M Bauer
Clinical Genitourinary Cancer. 2020-12-01 - 21 citationsSafety and Efficacy of Nivolumab in Patients With Advanced Clear Cell Renal Cell Carcinoma: Results From the Phase IIIb/IV CheckMate 374 Study.Joshua J McFarlane, Mark D Kochenderfer, Mark R Olsen, Todd M Bauer, Ana Molina
Clinical Genitourinary Cancer. 2020-12-01